Research programme: T1/ST2 inhibitors - Millennium PharmaceuticalsAlternative Names: T1/ST2 inhibitors research programme - Millennium Pharmaceuticals
Latest Information Update: 23 Aug 2002
At a glance
- Originator Millennium Pharmaceuticals
- Class Small molecules
- Mechanism of Action Interleukin 1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 10 Mar 2000 New profile
- 10 Mar 2000 Preclinical development for Asthma in USA (Unknown route)